Eocene Ltd(EOCN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.81 | Insider Own | 2.43% | Shs Outstand | 1.0M | Perf Week | -2.45% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.0M | Perf Month | -20.6% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 3.95% | Short Float | 0.82% | Perf Quarter | -42.89% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 0.25% | Short Ratio | 0.34 | Perf Half Y | -54.63% |
| Sales | 0.00B | P/B | 0.19 | EPS next 5Y | - | ROA | -55.03% | Short Interest | 0.01M | Perf YTD | -60.19% |
| Book/sh | 12.72 | P/C | 0.22 | EPS past 3/5Y | 73.46% 60.33% | ROE | -68.21% | 52W High | -80.6% ($12.32) | Perf Year | -74.02% |
| Cash/sh | 10.95 | P/FCF | - | Sales past 3/5Y | - | ROIC | -88.73% | 52W Low | 16.59% ($2.05) | Perf 3Y | -93.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 68.55% | Gross Margin | - | Volatility(W/M) | 15.78% 11.57% | Perf 5Y | -99.94% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.33 | Perf 10Y | -99.95% |
| Dividend Ex-Date | - | Quick Ratio | 4.16 | EPS Q/Q | 43.43% | Profit Margin | - | RSI (14) | 31.95 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.16 | Sales Q/Q | - | SMA20 | -17.16% ($2.89) | Beta | 0.72 | Target Price | $96 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/07/30 | SMA50 | -27.61% ($3.3) | Rel Volume | 0.14 | Prev Close | $2.48 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 8.33% - | SMA200 | -45.88% ($4.42) | Avg Volume(3M) | 0.02M | Price | $2.39 |
| IPO | 2014/3/13 | Option/Short | No/Yes | Trades | 64 | Volume | 3,434 | Change | -3.63% |
🩺 An Israel-based medical device and biotechnology company focused on gastrointestinal diseases. Originally starting as a developer of new drugs for liver diseases, the company shifted its business focus to the gastrointestinal field and is currently in the process of commercializing a medical device to protect anastomoses after colorectal surgery through its subsidiary, Colospan. Based on market capitalization, it belongs to the micro-cap category.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual. That is 14% of its average volume.
EOCN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
It ranks #566 of 597 in the industry
Based on market cap of $2M.
FAQ
What kind of company is EOCN?
EOCN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EOCN?
The market cap of EOCN is approximately $2M, ranking 5,747 within its sector.
What is the 52-week high and low for EOCN?
EOCN has recorded a 52-week high of $12.32 and a low of $2.05.
